143 related articles for article (PubMed ID: 2003981)
1. The distribution of alternative agents for targeted radiotherapy within human neuroblastoma spheroids.
Mairs RJ; Angerson W; Gaze MN; Murray T; Babich JW; Reid R; McSharry C
Br J Cancer; 1991 Mar; 63(3):404-9. PubMed ID: 2003981
[TBL] [Abstract][Full Text] [Related]
2. Differential penetration of targeting agents into multicellular spheroids derived from human neuroblastoma.
Mairs RJ; Angerson WJ; Babich JW; Murray T
Prog Clin Biol Res; 1991; 366():495-501. PubMed ID: 2068165
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
Weber W; Weber J; Senekowitsch-Schmidtke R
Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
[TBL] [Abstract][Full Text] [Related]
4. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
5. Enhanced tumour uptake and in vitro radiotoxicity of no-carrier-added [131I]meta-iodobenzylguanidine: implications for the targeted radiotherapy of neuroblastoma.
Mairs RJ; Russell J; Cunningham S; O'Donoghue JA; Gaze MN; Owens J; Vaidyanathan G; Zalutsky MR
Eur J Cancer; 1995; 31A(4):576-81. PubMed ID: 7576972
[TBL] [Abstract][Full Text] [Related]
6. Tumor spheroid model for the biologically targeted radiotherapy of neuroblastoma micrometastases.
Walker KA; Mairs R; Murray T; Hilditch TE; Wheldon TE; Gregor A; Hann IM
Cancer Res; 1990 Feb; 50(3 Suppl):1000s-1002s. PubMed ID: 2297711
[TBL] [Abstract][Full Text] [Related]
7. A tumour spheroid model for antibody-targeted therapy of micrometastases.
Walker KA; Murray T; Hilditch TE; Wheldon TE; Gregor A; Hann IM
Br J Cancer; 1988 Jul; 58(1):13-6. PubMed ID: 3166889
[TBL] [Abstract][Full Text] [Related]
8. Toxicity to neuroblastoma cells and spheroids of benzylguanidine conjugated to radionuclides with short-range emissions.
Cunningham SH; Mairs RJ; Wheldon TE; Welsh PC; Vaidyanathan G; Zalutsky MR
Br J Cancer; 1998 Jun; 77(12):2061-8. PubMed ID: 9649115
[TBL] [Abstract][Full Text] [Related]
9. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.
Roa WH; Miller GG; McEwan AJ; McQuarrie SA; Tse J; Wu J; Wiebe LI
Int J Radiat Oncol Biol Phys; 1998 May; 41(2):425-32. PubMed ID: 9607361
[TBL] [Abstract][Full Text] [Related]
10. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
11. Implications of the uptake of 131I-radiolabelled meta-iodobenzylguanidine (mIBG) for the targeted radiotherapy of neuroblastoma.
O'Donoghue JA; Wheldon TE; Babich JW; Moyes JS; Barrett A; Meller ST
Br J Radiol; 1991 May; 64(761):428-34. PubMed ID: 2036567
[TBL] [Abstract][Full Text] [Related]
12. A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.
Rutgers M; Gubbels AA; Hoefnagel CA; Voûte PA; Smets LA
Prog Clin Biol Res; 1991; 366():471-8. PubMed ID: 2068162
[No Abstract] [Full Text] [Related]
13. The biodistribution and pharmacokinetics of meta-iodobenzylguanidine in childhood neuroblastoma.
Lashford LS; Moyes J; Ott R; Fielding S; Babich J; Mellors S; Gordon I; Evans K; Kemshead JT
Eur J Nucl Med; 1988; 13(11):574-7. PubMed ID: 3350034
[TBL] [Abstract][Full Text] [Related]
14. Intracellular localization of metaiodobenzyl guanidine in human neuroblastoma cells by electron spectroscopic imaging.
Gaze MN; Huxham IM; Mairs RJ; Barrett A
Int J Cancer; 1991 Apr; 47(6):875-80. PubMed ID: 2010230
[TBL] [Abstract][Full Text] [Related]
15. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
16. Systemic administration of radionuclides in neuroblastoma as planned radiotherapeutic intervention.
Lashford LS; Clarke J; Kemshead JT
Med Pediatr Oncol; 1990; 18(1):30-6. PubMed ID: 2104648
[No Abstract] [Full Text] [Related]
17. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
18. The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G.
Mairs RJ; Gaze MN; Barrett A
Br J Cancer; 1991 Aug; 64(2):293-5. PubMed ID: 1892758
[No Abstract] [Full Text] [Related]
19. Interferon-gamma-induced differentiation of human neuroblastoma cells increases cellular uptake and halflife of metaiodobenzylguanidine.
Montaldo PG; Carbone R; Cornaglia Ferraris P; Ponzoni M
Cytotechnology; 1993; 11 Suppl 1():S140-3. PubMed ID: 7763744
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo studies with no-carrier added radioiodinated MIBG.
Franceschini R; Pecorale A; Chinol M; Calcagni ML; Servidei T; Riccardi R; Troncone L
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):72-7. PubMed ID: 9002755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
